Lipegfilgrastim: Pharmacodynamics and pharmacokinetics for body-weight-adjusted and 6 mg fixed doses in two randomized studies in healthy volunteers

Current Medical Research and Opinion

Volumn 30, Issue 12, 2014, Pages 2523-2533

  Buchner, Anton ^a   Lammerich, Andreas ^a   Abdolzade Bavil, Afsaneh ^b   Müller, Udo ^c   Bias, Peter ^a  

^a TEVA PHARMACEUTICALS   (Israel)

^b Department of Preclinical and Clinical Research   (Germany)

^c Teva Pharmaceuticals   (Germany)

Author keywords

Granulocyte colony stimulating factor; Human volunteers; Safety; Sustained release preparations

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PEGFILGRASTIM; RECOMBINANT PROTEIN;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; HALF LIFE TIME; HUMAN; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHIL; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SINGLE BLIND PROCEDURE; YOUNG ADULT;

ADOLESCENT; ADULT; AREA UNDER CURVE; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HALF-LIFE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; RECOMBINANT PROTEINS; REFERENCE VALUES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84914169226     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.962131     Document Type: Article

References (30)

1. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with highrisk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-31
2. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med 2013;368:1131-9
3. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64:328-40
4. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:e56-93
5. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002;13:903-9
6. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
7. Nemunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte- macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991;324:1773-8
8. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med 1992;116:177-82
9. Trillet-Lenoir V, Green J, Manegold C, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24
10. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 2010;21(Suppl 5):v248- 51
11. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205
12. Neulasta [package insert]. Thousand Oaks, CA: Amgen Inc., 2014
13. Yang BB, Kido A. Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 2011;50:295-306
14. Teva launches new biologicals in Europe and US. Generics and Biosimilars Initiative. Available at: http://www.gabionline.net/Biosimilars/News/Tevalaunches- new-biologicals-in-Europe-and-US [Last accessed 19 May 2014]
15. Assessment report: lonquex. European Medicines Agency. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002556/WC500148382.pdf [Last accessed 14 May 2014]
16. Buchner A, Bias P, Kaufmann M. A randomized, double-blind, active control, multicenter, dose-finding study of XM22, glycopegfilgrastim, in patients with breast cancer receiving myelosuppressive therapy [abstract 9080]. J Clin Oncol 2011;29:9080
17. Bondarenko I, Gladkov OA, Elaesser R, et al. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy. BMC Cancer 2013;13:386-98
18. Gladkov OA, Volovat C, Bondarenko IM, et al. Efficacy and safety of lipegfilgrastim in patients with lung cancer who are receiving chemotherapy [abstract 1014]. Support Care Cancer 2012;20:S243
19. Molineux G. The design and development of pegfilgrastim (PEG-rmetHuGCSF, Neulasta). Curr Pharm Des 2004;10:1235-44
20. Mueller U, Kohler E, Bias P, et al. Glyco-PEGylated R-metHuG-CSF (XM22/ lipegfilgrastim) - a novel long-acting once-per-cycle filgrastim: pharmacokinetics and pharmacodynamics for body weight adjusted doses and a 6mg fixed dose in health volunteers [abstract 1215]. Eur J Cancer 2011;47(Suppl 1):S149
21. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35
22. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996;5:213-26
23. Guideline on clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy (EMEA/ CPMP/555/95 Rev. 1). European Medicine Agency. Available at: www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/12/ WC500017738.pdf [Last accessed 15 October 2013]
24. Kroschinsky F, Holig K, Poppe-Thiede K, et al. Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors. Haematologica 2005;90:1665-71
25. Molineux G, Kinstler O, Briddell B, et al. A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 1999;27:1724-34
26. El-Ouriaghli F, Sloand E, Mainwaring L, et al. Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase. Blood 2003;102: 3786-92
27. Abdolzade-Bavil A, Cooksey BA, Scheckermann C, et al. Pegylated versus glycopegylated G-CSFs and their biochemical and physiological properties [abstract]. Blood 2013;122:4851
28. Volovat C, Bondarenko IM, Gladkov OA, et al. Efficacy and safety of lipegfilgrastim compared with placebo in elderly patients with non-small cell lung cancer receiving cisplatin/etoposide chemotherapy [poster]. Presented at the Annual Meeting of the International Society of Geriatric Oncology, Manchester, UK, 25-27 October 2012
29. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006;135:642-50
30. Dincer AP, Gottschall J, Margolis DA. Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. J Pediatr Hematol Oncol 2004;26:761-3